论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者血清中RASSF2基因启动子区域甲基化状况及其临床意义。方法:甲基化特异性聚合酶链反应(MSP)法检测62例NSCLC和30例肺部良性疾病患者及16名健康体检者血清中RASSF2启动子区域甲基化状况,并分析其与临床特征的关系。结果:RASSF2甲基化检出率在NSCLC患者中为38.71%(24/62),而肺部良性疾病患者和健康体检者血清未检出,χ2=22.89,P<0.01。NSCLC患者血清RASSF2基因甲基化检出率与年龄、性别、病理类型、临床分期和分化程度无明显相关(P>0.05),不吸烟者RASSF2甲基化率高于吸烟者(61.90%vs 26.83%,χ2=7.20,P<0.05)。结论:RASSF2甲基化可能在NSCLC发生、发展中起重要作用,有望成为NSCLC辅助诊断的分子标记。
Objective: To investigate the methylation status of RASSF2 promoter in serum of patients with non-small cell lung cancer (NSCLC) and its clinical significance. Methods: Methylation-specific polymerase chain reaction (MSP) was used to detect the methylation status of RASSF2 promoter in serum of 62 patients with NSCLC, 30 patients with benign lung diseases and 16 healthy controls, and their clinical characteristics Relationship. Results: The detection rate of methylation of RASSF2 was 38.71% (24/62) in patients with NSCLC, while no serum was detected in patients with benign lung diseases and healthy subjects (χ2 = 22.89, P <0.01). The methylation rate of RASSF2 gene in NSCLC patients was not significantly correlated with age, gender, pathological type, clinical stage and degree of differentiation (P> 0.05). The methylation rate of RASSF2 was higher in non-smokers than in smokers (61.90% vs 26.83 %, χ2 = 7.20, P <0.05). Conclusion: Methylation of RASSF2 may play an important role in the occurrence and development of NSCLC, which is expected to become a molecular marker for the diagnosis of NSCLC.